Open AccessSafety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial
Author(s) -
John S. Bradley,
Helen Broadhurst,
Karen Cheng,
María José Méndez,
Paul Newell,
M Prchlík,
Gregory G. Stone,
Angela K Talley,
Margaret Tawadrous,
Dalia Wajsbrot,
Katrina Yates,
Antonina Zuzova,
Annie Gardner
Publication year - 2019
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000002392
Subject(s) - ceftazidime/avibactam , metronidazole , medicine , ceftazidime , meropenem , avibactam , adverse effect , tolerability , randomized controlled trial , surgery , anesthesia , antibiotics , pseudomonas aeruginosa , microbiology and biotechnology , biology , genetics , antibiotic resistance , bacteria
Ceftazidime-avibactam plus metronidazole is effective in the treatment of complicated intra-abdominal infection (cIAI) in adults. This single-blind, randomized, multicenter, phase 2 study (NCT02475733) evaluated the safety, efficacy and pharmacokinetics of ceftazidime-avibactam plus metronidazole in children with cIAI.